Cisplatin Articles
Mixed fortunes for Roche’s Avastin; Xeloda recommended by EU
26 February 2010
UK’s NICE says “no” to Novartis’ Afinitor for advanced RCC and delays Sprycel and Tasigna; Scotland backs Alimta and Stelara
9 February 2010
Pfizer drops figitumumab in NSCLC on disappointing Ph III; FDA delays Prevnar 13 and rejects Basilea/J&J’s ceftobiprole for cSSSI
4 January 2010
UK’s NICE backs GSK’s Hycamtin for cervical cancer and Lilly’s Efient for preventing blood clots
28 October 2009
Boehringer Ingelheim to start Ph II study with Tovok
4 August 2009
Omega-3 can kill cancer cells, says study
14 April 2009
Palonosetron prevents CINV and boosts food intake in highly-emetogenic chemo patients, study finds
30 March 2009
AGI's CID drug shows benefit at higher dose
23 March 2009
IDM gets EU appro for Mepact; seeking partner
23 March 2009
Merck Serono expands cilengitide program
23 March 2009
IDM gets EMEA nod, now looking to FDA
24 November 2008
Lilly gets third appro for Alimta
6 October 2008
Transgene's NSCLC vacc boosts survival after 17 months
22 September 2008
US FDA allows Ph II for Sound's hearing loss drug
18 August 2008
Tavocept increases survival by 198 days
28 July 2008
Strong mid-stage data on Nexavar
9 June 2008
Alimta boosts survival in certain NSCLC types
9 June 2008
Roche's Avastin fails to show overall survival
28 April 2008
44% bioavailability for Poniard's picoplatin
21 April 2008
EMEA clears histology-based use for Alimta
21 April 2008
Caraco's launches Sun Pharma's generic Ethyol
14 April 2008
Pfizer moves to keep market share in Japan
24 March 2008
New histology-based use for Alimta
3 March 2008
FDA clears Merck & Co's Emend Injection for CINV
4 February 2008
VQD-002 impresses in chemotherapy- resistance trial
28 January 2008
Promising Ph IIb data on Transgene NSCLC vacc
21 January 2008
Barr's generic Kytril gains final FDA approval
7 January 2008
Adherex opens Ph III STS trial
5 November 2007
HGS cancer MAb's impress in trials
5 November 2007
CT's bis-platinate drugs show activity against resistant tumors
5 November 2007
CHMP recommends Taxotere SCCHN approval expansion
29 October 2007
Lilly files Alimta with EMEA for NSCLC
1 October 2007
Genmab initiates Ph III trial of zalutumumab
24 September 2007
Erbitux meets Ph III NSCLC trial endpoints
17 September 2007
World Conference on Lung Cancer highlights important developments
17 September 2007
OVATUREtrial.com drug trial web site launched
10 September 2007
Potential for phenoxodiol to protect against neuropathy
20 August 2007
CHMP recommends approval of Avastin for NSCLC
30 July 2007
US orphan status for BTG's plevitrexed
18 June 2007
Preclinical data suggests combo role for Proxinium
23 April 2007
Erbitux increases overall survival in SCCHN
16 April 2007
Headlines 25 years ago this week....
26 March 2007
GSK initiates Ph III trial of Tykerb
5 March 2007
Xeloda gets nod for stomach cancer in Europe
5 March 2007
Strong data for Avastin may lead to lower dose
5 March 2007
Abraxis launches generic ondansetron injection in USA
8 January 2007
Hycamtin gets EU OK for cervical cancer
11 December 2006
Introgen's NPRL2 shows promise
27 November 2006
Japan's generic drugs market expected to grow 8.8% from 2006 to 2008
27 November 2006
Lilly's Almita enters Ph III trial for SCLC
30 October 2006
US FDA fast-tracks Novelos' NOV-002
14 August 2006
Tavocept falls short in Ph III neuropathy trials
7 August 2006
Xeloda filed in EU for stomach cancer
31 July 2006
Nerviano to develop two novel Indena drugs
24 July 2006
Expanded US label for GSK's Hycamtin
26 June 2006
Roche's Xeloda sees strong Ph III data
12 June 2006
Lilly's enzastaurin: good combo drug at Ph I
12 June 2006
Japan stock market week to April 17, 2006
24 April 2006
Roche's Xeloda performs well in Ph III
17 April 2006
FDA accepts sNDA on GSK's Hycamtin
27 February 2006
NanoCarrer's NC-6004 IND accepted by MHRA
6 February 2006
FDA OKs Merck & Co's Emend in combination
16 January 2006
Sanofi's Taxotere gets priority review for advanced gastric cancer
12 December 2005
Transgene provides clinical pipeline update
12 December 2005
Scotland OKs Xeloda but fears in England/Wales
15 August 2005
OncoGenex starts treating in Ph II trial of anticancer drug
15 August 2005
Promising interim data for Telik's Telcyta
11 July 2005
Marshall Edwards drug effective in cancer
16 May 2005
Alfacell's Onconase shows activity against NSCLC
25 April 2005
Targretin: endpoints missed in NSCLC trials
4 April 2005
AustCancer and Bioaccelerate announce positive results
14 February 2005
Lilly's Alimta OKed in EU for two indications
27 September 2004
FDA OKs 2nd indication for Lilly's Alimta
30 August 2004
New use for Gemzar OKed in Europe
9 August 2004
Lilly's Alimta gets positive opinion in EU
5 July 2004
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Italy's pharma market slump set to continue, warns GlobalData
